For research use only. Not for therapeutic Use.
Papaverine hydrochloride（Cat No.:I004309）is a smooth muscle relaxant and vasodilator primarily used in the treatment of conditions like erectile dysfunction, vasospasm, and certain types of vascular disorders. It works by inhibiting phosphodiesterase enzymes, which results in increased cyclic AMP levels, leading to the relaxation of smooth muscles and dilation of blood vessels. Papaverine has been used to treat ischemic conditions, such as coronary artery spasms, and is sometimes used in combination with other treatments for erectile dysfunction. It can be administered orally or via injection, with side effects including hypotension and gastrointestinal disturbances.
| Catalog Number | I004309 |
| CAS Number | 61-25-6 |
| Molecular Formula | C20H22ClNO4 |
| Purity | ≥95% |
| Target | PDE |
| Solubility | DMSO: ≤ 6.4 mg/mL (Need ultrasonic and warming) |
| Storage | Store at -20°C |
| IUPAC Name | 1-[(3,4-dimethoxyphenyl)methyl]-6,7-dimethoxyisoquinoline;hydrochloride |
| InChI | InChI=1S/C20H21NO4.ClH/c1-22-17-6-5-13(10-18(17)23-2)9-16-15-12-20(25-4)19(24-3)11-14(15)7-8-21-16;/h5-8,10-12H,9H2,1-4H3;1H |
| InChIKey | UOTMYNBWXDUBNX-UHFFFAOYSA-N |
| SMILES | COC1=C(C=C(C=C1)CC2=NC=CC3=CC(=C(C=C32)OC)OC)OC.Cl |
| Reference | </br>1:Prediction of the hydroxypropyl cellulose-poly(vinyl alcohol) ratio in aqueous solution containing papaverine hydrochloride in terms of drug loaded electrospun fiber formation. Kazsoki A, Szabó P, Zelkó R.J Pharm Biomed Anal. 2017 May 10;138:357-362. doi: 10.1016/j.jpba.2017.02.030. Epub 2017 Feb 22. PMID: 28259094 </br>2:THE PROCESS OF MASS TRANSFER ON THE SOLID-LIQUID BOUNDARY LAYER DURING THE RELEASE OF DICLOFENAC SODIUM AND PAPAVERINE HYDROCHLORIDE FROM TABLETS IN A PADDLE APPARATUS. Kasperek R, Zimmer L, Poleszak E.Acta Pol Pharm. 2016 Jan-Feb;73(1):163-73. PMID: 27008811 </br>3:Influence of Polymer Type on the Physical Properties and Release Profile of Papaverine Hydrochloride From Hard Gelatin Capsules. Polski A, Iwaniak K, Kasperek R, Modrzewska J, Sobótka-Polska K, Sławińska K, Poleszak E.Polim Med. 2015 Jul-Dec;45(2):51-5. PMID: 26994886 Free Article</br>4:PHARMACOKINETICS OF DICLOFENAC SODIUM AND PAPAVERINE HYDROCHLORIDE AFTER ORAL ADMINISTRATION OF TABLETS TO RABBITS. Kasperek R, Zimmer Ł, Jawień W, Poleszak E.Acta Pol Pharm. 2015 May-Jun;72(3):527-38. PMID: 26642661 Free Article</br>5:Dissolution Studies of Papaverine Hydrochloride from Tablets in Three Pharmacopoeia Apparatuses. Polski A, Kasperek R, Rogowska M, Iwaniak K, Sobòtka-Polska K, Poleszak E.Polim Med. 2015 Jan-Jun;45(1):21-4. PMID: 26630725 Free Article</br>6:Release kinetics of papaverine hydrochloride from tablets with different excipients. Kasperek R, Polski A, Zimmer Ł, Poleszak E.Sci Pharm. 2014 May 16;82(3):684-96. doi: 10.3797/scipharm.1310-19. Print 2014 Jul-Sep. PMID: 25853076 Free PMC Article</br>7:The effect of excipients on the release kinetics of diclofenac sodium and papaverine hydrochloride from composed tablets. Kasperek R, Trebacz H, Zimmer Ł, Poleszak E.Acta Pol Pharm. 2014 May-Jun;71(3):439-49. PMID: 25265824 Free Article</br>8:[Influence of polymer type on the physical properties and the release study of papaverine hydrochloride from tablets]. Kasperek R, Polski A, Sobótka-Polska K, Poleszak E.Polim Med. 2014 Jan-Mar;44(1):5-12. Polish. PMID: 24918651 Free Article</br>9:Treatment of loin pain suspected to be renal colic with papaverine hydrochloride: a prospective double-blind randomised study. Asgari SA, Asli MM, Madani AH, Maghsoudi PA, Ghanaei MM, Shakiba M, Aval HB, Enshaei A, Farzan A, Esmaeili S.BJU Int. 2012 Aug;110(3):449-52. doi: 10.1111/j.1464-410X.2011.10793.x. Epub 2012 Feb 20. PMID: 22348304 Free Article</br>10:Simultaneous release of diclofenac sodium and papaverine hydrochloride from tablets and pellets using the flow-through cell apparatus described by dimensionless equations. Kasperek R.Acta Pol Pharm. 2011 Mar-Apr;68(2):261-72. PMID: 21485300 Free Article |
